Atricure to Acquire SentreHEART for Expansion of Therapies to Treat Atrial Fibrillation

 Atricure to Acquire SentreHEART for Expansion of Therapies to Treat Atrial Fibrillation

Atricure to Acquire SentreHEART for Expansion of Therapies to Treat Atrial Fibrillation

Shots:

  • Atricure acquires SentreHEART in all stock and cash transaction. Atricure to pay upfront as ~$40M in cash and AtriCure common stock, ~$140M milestones based on aMAZE IDE clinical trial including PMA approval, and ~$120M is based on a milestone related to reimbursement for the therapy involving SentreHEART devices
  • The focus of the acquisition is to strengthen and expand the product portfolio of Atricure, addressing therapies for the treatment of atrial fibrillation
  • The LARIAT Suture Delivery Device is an elegant and intuitive suture-based solution to soft-tissue closure, compatible with a wide range of anatomical shapes offering immediate, complete closure, with no metal, clip, or implant left behind and is currently evaluated in aMAZE trial for LAA closure adjunctive to PVI catheter ablation treating persistent and longstanding persistent Afib

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post